VIVELLE
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 46m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVELLE is a transdermal estradiol patch approved in 2000 for hormone replacement therapy and related indications. It delivers estradiol via an extended-release film formulation applied to the skin. The drug works by replacing or supplementing endogenous estrogen in patients with estrogen deficiency.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the VIVELLE team is likely stabilizing operations and preparing for market transition; smaller team focus expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIVELLE offers exposure to mature product lifecycle management in a legacy but stable market. Career value lies in managing LOE transition, generic competition strategies, and optimizing commercial execution in a declining-growth environment.
Brand ManagerProduct Manager
Worked on VIVELLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.